bioerodible

bioerodible

adjective Referring to polymers that exhibit controlled degradation by incorporating pro-degradant additive master batches or concentrates. Such polymers oxidise and embrittle in the environment and erode under by weathering.
References in periodicals archive ?
NASDAQ: BDSI) today presented data from a Phase 2 study for the investigational drug buprenorphine HCl buccal film utilizing BDSI's patented BioErodible MucoAdhesive (BEMA[sup.
Independently, pSivida is developing an injectable, sustained release product to treat uveitis affecting the back of the eye (posterior uveitis) and an injectable, bioerodible product to treat glaucoma and ocular hypertension in collaboration with Pfizer.
Lux will access the technology, the expertise, and the state of the art infrastructure at the Center to develop bioerodible, polymers capable of eluting drug molecules as a platform for ophthalmic drug products.
An investigator-sponsored clinical trial is ongoing for an injectable, bioerodible microinsert to treat glaucoma and ocular hypertension, a product candidate on which Pfizer Inc.
Tethadur utilizes an injectable, bioerodible, nanostructured, porous BioSilicon material for drug delivery.
BUNAVAIL uses BDSI's patented BioErodible MucoAdhesive (BEMA) drug delivery technology to deliver buprenorphine across the buccal mucosa (inside lining of the cheek).
The Company has additional research and development programs that utilize its bioerodible, injectable and implantable delivery systems.
NASDAQ:PSDV) (ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that it has entered into a technology evaluation agreement for its bioerodible Durasert[TM] drug delivery technology in ophthalmology with Neuron Systems, Inc.
BEMA Buprenorphine is a transmucosal form of buprenorphine, a partial mu-opiate receptor agonist, which incorporates a bioerodible mucoadhesive (BEMA) technology.
NASDAQ:PSDV; ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that it has signed a funded technology evaluation agreement with a leading global pharmaceutical company to evaluate pSivida's bioerodible Durasert[TM] drug delivery technology in ophthalmology.
MacroMed's technology platform includes ReGel(R), a temperature-sensitive, bioerodible hydrogel, HySolv(TM), a drug solubilizer, and SQZGel(TM), an oral sustained-release technology.